Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00781339 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of NVC-422 on Bacteriuria in Catheterized Patients
A Phase 2 study, sponsored by NovaBay Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00781339 is a Phase 2 study that has completed, run by NovaBay Pharmaceuticals. The registered enrollment target is 20 participants.
The verdict
NCT00781339, a Phase 2 study, has completed, sponsored by NovaBay Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to study the effects of NVC-422 instilled into the bladder in reducing bacteria in the urine.
Interventions
- DRUG sodium 2-(dichloroamino)-2-methylpropane-1-sulfonate monohydrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2008-10 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00781339
The ClinicalTrials.gov registry entry for NCT00781339 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NovaBay Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sodium 2-(dichloroamino)-2-methylpropane-1-sulfonate monohydrate is the first listed.
NCT00781339 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00781339 about?
NCT00781339 is a clinical study titled "Safety and Efficacy Study of NVC-422 on Bacteriuria in Catheterized Patients". The purpose of this clinical trial is to study the effects of NVC-422 instilled into the bladder in reducing bacteria in the urine.
What is the current status of trial NCT00781339?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2008-10. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00781339?
The interventions under investigation include: sodium 2-(dichloroamino)-2-methylpropane-1-sulfonate monohydrate (DRUG).
Who is sponsoring clinical trial NCT00781339?
This trial is sponsored by NovaBay Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.